Effect on quality of life (QOL) of adding cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): A joint analysis of the multicentre, randomized, phase 3 MILES-3 and MILES-4 studies
Maria Carmela Piccirillo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), Andrea Luciani(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Floriana Morgillo(University of Campania "Luigi Vanvitelli"), Federica Perrone(University of Bari Aldo Moro), Ciro Gallo(University of Campania "Luigi Vanvitelli"), Laura Arenare(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Paolo Maione(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Agnese Montanino(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alessandro Morabito(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Laura Bonanno(Louisiana State University), Francesco Rosetti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Anna Manzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), M.A. Burgio(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Silvana Leo(Ospedale Vito Fazzi), Luigi Cavanna(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Simona Signoriello(University of Campania "Luigi Vanvitelli"), E. Piazza(Luigi Sacco Hospital), Saverio Cinieri(Ospedale A. Perrino)
Cited by 1
Related Papers
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452